Joseph Mikhael, MD, discusses the latest trends and innovations regarding multiple myeloma management.
EHA 2024: Highlights in Multiple Myeloma
Joseph Mikhael, MD, discusses the latest trends and innovations regarding multiple myeloma management.
Joseph Mikhael, MD, discusses the PERSEUS trial findings presented at EHA 2024.
Dr. Mikhael discusses treatment in early relapse of multiple myeloma.
Dr. Mikhael discusses the safety and usefulness of tesclistimab in patients with high-risk refractory multiple myeloma.
Dr. Mikhael outlines the significant hurdles in bispecific antibody therapy, as presented at the European Hematology Association's 2024 conference.
Dr. Mikhael discusses EHA 2024 data he found particularly noteworthy to share with colleagues.
Advertisement
Advertisement
Trending on AJMC
1
CAR T-Cell Therapy Holds Potential in SCLC, but Significant Barriers Remain
2
Value-Based Care Interventions and Management of CKD Progression
3
New Partnership Model Boosts Maternal Outcomes in Medicaid ACOs
4
CDC Reports Largest Pediatric Influenza-Associated Encephalopathy Case Series in 2024-2025 Season
5
